Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?

Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Immix Biopharma completed enrollment for its NEXICART-2 Phase 2 clinical trial, a key step toward seeking regulatory approval for NXC-201. This therapy targets relapsed/refractory AL Amyloidosis, a condition where the immune system produces toxic proteins that cause organ failure. Topline results from the 40-patient study are expected in Q3 2026, which will be followed by a BLA submission and a planned commercial launch.

NXC-201 is a specialized CAR-T cell therapy designed to eliminate the source of toxic light chains in patients. The treatment has already received several high-priority regulatory labels, including Breakthrough Therapy and Orphan Drug designations from the FDA and EMA. If successful, it would become the first FDA-approved treatment specifically for the relapsed/refractory stage of this disease.

To lead the upcoming regulatory and commercial phases, the company appointed Dr. Richard Graydon as Chief Medical Officer. Dr. Graydon brings extensive experience from Merck and Johnson & Johnson, where he oversaw the approval of major oncology drugs like Keytruda and Darzalex. His expertise is expected to be vital as Immix Biopharma Inc. (NASDAQ:IMMX) transitions from a clinical-stage company to a commercial entity following the anticipated BLA filing.

Immix Biopharma Inc. (NASDAQ:IMMX) is a clinical-stage biotechnology company focused on treating relapsed/refractory AL Amyloidosis. Its lead candidate, NXC-201, is a BCMA-targeted CAR-T cell therapy designed to eliminate the source of toxic light chains that cause organ failure.

While we acknowledge the potential of IMMX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.